Decreased WWOX expression promotes angiogenesis in osteosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• WW domain-containing oxidoreductase (WWOX) is recognized as a crucial tumor suppressor in various cancers.
• Osteosarcoma is a primary bone malignancy with significant metastatic potential.

Purpose of the Study:

• To investigate the role of WWOX in osteosarcoma progression, focusing on its effects on angiogenesis and invasion.
• To determine the correlation between WWOX expression and clinicopathological features, patient survival, and specific molecular markers in osteosarcoma.

Main Methods:

• Analysis of WWOX expression in 201 osteosarcoma patient samples.
• In vitro studies using MG-63 osteosarcoma cells to assess WWOX function.
• Investigation of WWOX promoter methylation and its association with WWOX expression.
• Co-culture experiments with HUVEC cells to evaluate angiogenesis.
• Correlation analysis with markers including RUNX2, VEGF, OPN, and bcl-2.

Main Results:

• WWOX expression was negatively correlated with RUNX2 and VEGF, and positively associated with response to neoadjuvant chemotherapy and disease-free survival.
• WWOX overexpression inhibited osteosarcoma cell invasion, promoted apoptosis, and suppressed VEGF and OPN expression in vitro.
• WWOX promoter methylation was linked to reduced WWOX expression in osteosarcoma.
• Overexpression of WWOX reduced angiogenesis in vitro and was associated with decreased microvessel density (MVD) in patient tissues.

Conclusions:

• Reduced WWOX expression in osteosarcoma is associated with increased invasion, suppressed apoptosis, and elevated angiogenesis (MVD).
• WWOX functions as a tumor suppressor in osteosarcoma, potentially through modulation of angiogenesis and invasion pathways.
• WWOX expression is regulated by promoter methylation and serves as a prognostic biomarker for osteosarcoma patients.